0QW0.L - argenx SE
| Chiusura precedente | 365,91 |
| Aperto | 362,30 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 362,20 - 366,50 |
| Intervallo di 52 settimane | 362,20 - 366,50 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 137,523M |
| Beta (5 anni mensile) | 0,46 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -11,03 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireargenx to Present at Upcoming Investor Conferences
May 31, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in two upcoming investor conferences in June: William Blair 43rd Annual Growth Stock Conference. Presentation on Tuesday, June 6, 2023 at 1:20 p.m. CT in Chicago, IL.Jefferies Healthcare Conference. Fireside chat on Wednesday, June 7, 2023 at 3:00 p.m
- GlobeNewswire
argenx Reports First Quarter 2023 Financial Results and Provides Business Update
$218 million in first quarter VYVGART® (efgartigimod alfa-fcab) global net product sales VYVGART received marketing authorization in Israel through partnership with Medison88 events achieved in ADHERE trial; topline data now expected in July 2023Enrollment completed in ADVANCE-SC and ADDRESS trials; topline data from both expected in fourth quarter of 2023Management to host conference call today at 2:30 pm CET (8:30 am ET) Regulated Information/Inside InformationMay 4, 2023 Amsterdam, the Nether
- GlobeNewswire
argenx announces results of Annual General Meeting of Shareholders
May 3, 2023 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders held yesterday. All items on the agenda received a majority of votes in favor except for agenda item 3 (advisory non-binding vote on the 2022 remuneration report). As part of the approved resolutions: The Company's annual report and annual
- GlobeNewswire
argenx to Present at BofA Securities 2023 Health Care Conference
May 2, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the BofA Securities 2023 Health Care Conference on Tuesday, May 9, 2023, at 8:00 a.m. P.T. in Las Vegas, NV. A live webcast of the fireside chat may be accessed on the Investors section of the argenx website at argenx.com/investor
- GlobeNewswire
argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023
April 27, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 4, 2023 at 2:30 pm CET (8:30 am ET) to discuss its first quarter 2023 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com
- GlobeNewswire
argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting
Amsterdam, the Netherlands – [04/18/2023] argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will present six abstracts further demonstrating its long-term commitment to the generalized myasthenia gravis (gMG) community during the 75th American Academy of Neurology (AAN) Annual Meeting, which is taking place from April 22-27, 2023 in Boston, MA. The presentations include cl
- GlobeNewswire
argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
Genmab and argenx have entered into a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody therapies Discovery programs against two differentiated targets are underway Amsterdam, the Netherlands – 04/17/2023 argenx SE (Euronext & Nasdaq: ARGX) and Genmab A/S (Nasdaq: GMAB) announced today that argenx and Genmab have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with appl
- GlobeNewswire
argenx Announces Annual General Meeting of Shareholders on May 2, 2023
March 17, 2023 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that an Annual General Meeting of shareholders will be held at 12:00 PM CET on Tuesday, May 2, 2023 at Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands. The shareholders and all other persons with meeting rights are invited to attend the Annual Genera
- GlobeNewswire
argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis
VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in the UK for the treatment of adults living with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive 68% of anti-AChR antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale compared with 30% of patients treated with placebo (n=19/64) (p<0.0001) during the first treatment cycle in the Phase 3 ADAPT
- GlobeNewswire
argenx Announces Planned Transition of Chief Operating Officer
Karen Massey appointed as Chief Operating Officer, effective March 13, 2023Keith Woods to retire and serve as Advisor on argenx Board of Directors March 2, 2023 Amsterdam, the Netherlands — argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey will join argenx as Chief Operating Officer, effective March 13, 2023. Ms. Massey will succeed Keith Woods, who will remain at a
- GlobeNewswire
argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update
$173 million in fourth quarter and $401 million in full year 2022 VYVGART® (efgartigimod alfa-fcab) global net product sales FDA review ongoing for SC efgartigimod BLA with PDUFA target action date of June 20, 2023; MAA filed in Japan with approval decision expected by first quarter of 2024 ADHERE topline results continue to be expected in second quarter of 2023 Karen Massey appointed as Chief Operating Officer as part of planned transition; Keith Woods to retire and serve as advisor on Board of
- GlobeNewswire
argenx Appoints Steve Krognes to Board of Directors
February 27, 2023 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 12:00pm CET, Steve Krognes was appointed as a non-executive director to its Board of Directors. He will also become the chairperson of the Audit and Compliance Committee. As a result of the appointment of Mr. Krognes
- GlobeNewswire
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
February 23, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, March 2, 2023 at 2:30 pm CET (8:30 am ET) to discuss its full year 2022 financial results and provide a fourth quarter business update. A webcast of the live call may be accessed on the Investors section of the argenx websi
- GlobeNewswire
argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
January 27, 2023 Amsterdam, the Netherlands — argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the review of the Biologics License Application (BLA) for subcutaneous (SC) efgartigimod (1000mg efgartigimod-PH20) for the treatment of adult patients with generalized myasthenia gravis (gMG) to June 20, 2023. The FDA notified
- GlobeNewswire
argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
January 16, 2023 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an extraordinary general meeting of shareholders will be held at 12:00 PM CET on Monday, February 27, 2023 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the e
- GlobeNewswire
argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
Reported $402 million in preliminary* full-year 2022 global net VYVGART sales ADHERE topline results now expected in second quarter of 2023; Stage B enrollment has surpassed projected target of 130 patients Registrational trial of efgartigimod in thyroid eye disease (TED) to start in 2023; additional proof-of-concept trials to start in ANCA-associated vasculitis and antibody mediated rejection (AMR) Submission for marketing approval in Japan of VYVGART for immune thrombocytopenia (ITP) expected
- GlobeNewswire
argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
January 3, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:00 a.m. PT. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A repla
- GlobeNewswire
argenx Appoints Ana Cespedes to Board of Directors
December 12, 2022 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 12:00pm CET, Ana Cespedes was appointed as non-executive director to its Board of Directors. Ana Cespedes brings robust experience across a broad range of critical areas for commercialization and access, as well as f
- GlobeNewswire
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
First immune thrombocytopenia (ITP) plenary selection in 15 years underscores significant unmet need in this rare, serious autoimmune bleeding disease VYVGART showed rapid, clinically and statistically significant improvements in platelet counts compared with placebo; safety profile consistent with previous trials Topline data from ADVANCE-SC trial of subcutaneously (SC) administered VYVGART for ITP expected in second half of 2023 Amsterdam, the Netherlands – December 10, 2022 – argenx SE (Euron
- GlobeNewswire
argenx Enters Into Agreement To Acquire Priority Review Voucher
Amsterdam, the Netherlands – November 30, 2022 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an agreement to acquire a U.S. Food and Drug Administration (FDA) Priority Review Voucher (PRV) for $102 million. A PRV entitles the holder to FDA priority review of a single Biologics License Application (BLA), which reduces the target review period and may lead to an expedited appr
- GlobeNewswire
argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
- Prescription Drug User Fee Act (PDUFA) target action date is March 20, 2023 - Submission based on positive results from the Phase 3 bridging study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered efgartigimod compared to intravenous (IV) administration November 22, 2022 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, to
- GlobeNewswire
argenx Reports Third Quarter 2022 Financial Results and Provides Business Update
$131 million in third quarter VYVGART® (efgartigimod alfa-fcab) global net product sales Filed Biologics License Application (BLA) for subcutaneous (SC) efgartigimod for treatment of generalized myasthenia gravis (gMG)Hans de Haard, Ph.D. to retire as Chief Scientific Officer (CSO) in January 2023Management to host conference call today at 2:30 pm CET (8:30 am ET) October 27, 2022 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving
- GlobeNewswire
argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022
October 20, 2022Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, October 27, 2022 at 2:30 pm CET (8:30 am ET) to discuss its third quarter 2022 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at arg
- GlobeNewswire
argenx to Highlight Key Programs from Neuromuscular Franchise at Upcoming Medical Meetings
Scientific presentations demonstrate argenx’s leadership in FcRn blockade and commitment to innovating for patients across multiple neuromuscular diseases Additional data from ADAPT+ open-label study support long-term safety of VYVGART® (efgartigimod alfa-fcab) for treatment of adult patients with generalized myasthenia gravis (gMG), who experienced consistent improvements in function and strength over multiple years Pooled data from ADAPT studies and real-world clinical setting suggest VYVGART
- GlobeNewswire
argenx Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis
Submission package based on positive data from the Phase 3 ADAPT-SC trial demonstrating noninferiority of subcutaneous (SC) efgartigimod compared to intravenously administered VYVGART® (efgartigimod alfa-fcab) based on total immunoglobulin G (IgG) reduction at day 29 Amsterdam, the Netherlands – September 21, 2022 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the submission